Collaborative, Licensing and Other Arrangements (Tables)

6 Months Ended

Jun. 30, 2026

The following table summarizes total other revenue recognized for the three and six months ended June 30, 2026 and 2025:


	Three Months Ended		Six Months Ended
	June 30,		June 30,
		2026	2025	2026	2025
Other Revenue		$	$	$	$
Amgen royalty revenue		18,823	9,033	37,120	14,552
Novartis broad markets revenue		4,956	3,320	10,219	6,842
Other		1,498	871	4,047	579
Other Revenue		25,277	13,224	51,386	21,973

The table below presents the Company’s net product revenue for the three and six months ended June 30, 2026 and 2025:


	Three Months Ended		Six Months Ended
	June 30,		June 30,
		2026	2025	2026	2025
		$	$	$	$
Product revenue – gross		2,205,600	1,657,838	4,099,089	3,057,904
Less: rebates and sales returns		(525,806)	(355,762)	(931,966)	(647,298)
Product revenue – net		1,679,794	1,302,076	3,167,123	2,410,606

The following table disaggregates net product revenue by product for the three and six months ended June 30, 2026 and 2025:


	Three Months Ended		Six Months Ended
	June 30,		June 30,
		2026	2025	2026	2025
		$	$	$	$
BRUKINSA®		1,247,640	949,840	2,342,483	1,741,504
TEVIMBRA®		228,515	193,524	434,756	364,688
XGEVA®		104,499	81,318	194,419	151,741
BLINCYTO®		36,537	25,587	70,572	49,493
KYPROLIS®		15,147	19,416	32,118	39,144
POBEVCY®		9,633	11,242	21,760	24,987
Other		37,823	21,149	71,015	39,049
Total product revenue – net		1,679,794	1,302,076	3,167,123	2,410,606

Schedule of Collaboration Agreements

Amounts recorded related to the Company’s portion of the co-development funding on the pipeline assets for the three and six months ended June 30, 2026 and 2025 were as follows:


	Three Months Ended		Six Months Ended
	June 30,		June 30,
		2026	2025	2026		2025
		$	$	$		$
BeOne’s portion of the development funding		59,818	52,196	117,866		92,715
Less: Amortization of research and development cost share liability		29,518	25,757	58,163		45,569
Research and development expense		30,300	26,439	59,703		47,146

						As of
						June 30, 2026
						$
Remaining portion of development funding cap					12,527

As of June 30, 2026 and December 31, 2025, the research and development cost share liability recorded in the Company’s balance sheet was as follows:


	As of
	June 30,	December 31,
	2026	2025
	$	$
Research and development cost share liability, current portion	6,182	64,345

Total research and development cost share liability	6,182	64,345

Schedule of Amounts and Classification of Reimbursement Expense

The total reimbursement paid under the commercial profit-sharing agreement for product sales is classified in the income statement for the three and six months ended June 30, 2026 and 2025 as follows:


	Three Months Ended		Six Months Ended
	June 30,		June 30,
		2026	2025	2026	2025
		$	$	$	$
Cost of sales - product		12,660	9,533	23,913	17,027
Research and development		(1,132)	(1,597)	(1,325)	(2,109)
Selling, general and administrative		(27,083)	(25,037)	(53,525)	(48,985)
Total		(15,555)	(17,101)	(30,937)	(34,067)

Schedule of Payments Due to Collaboration Partners

Upfront and milestone payments incurred under these arrangements for the three and six months ended June 30, 2026 and 2025 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or term of the commercialization agreements.


		Three Months Ended		Six Months Ended
		June 30,		June 30,
			2026	2025	2026	2025
Payments due to collaboration partners	Classification		$	$	$	$
Upfront payments	Research and development expense		19,974	500	20,518	500
Development milestones incurred	Research and development expense		3,313	—	3,313	—
Regulatory and commercial milestone payments	Intangible asset		—	20,000	—	20,000
Total			23,287	20,500	23,831	20,500